Marker Therapeutics Crecimiento futuro

Future controles de criterios 2/6

Se prevé que los beneficios de Marker Therapeutics disminuyan a un ritmo anual de 38.9%, mientras que sus ingresos anuales crecerán a un ritmo de 70.7% por año. Se espera que el BPA disminuya en un 10.4% al año.

Información clave

-38.9%

Tasa de crecimiento de los beneficios

-10.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	26.8%
Tasa de crecimiento de los ingresos	70.7%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	15 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Oct 04

Marker Therapeutics awarded $2M FDA grant for leukemia candidate

Sep 13

Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71M

Aug 11

Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky

Jun 17

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Mar 04

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Nov 19

Marker Therapeutics: Passing Through A Catalyst Desert

Oct 22

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Aug 17

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

May 04

Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?

Feb 22

Marker shares rise as it completes construction of its cGMP manufacturing facility

Jan 13

FDA lifts partial hold on Marker Therapeutics's leukemia trial with cell therapy

Jan 05

Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?

Dec 29

Marker Therapeutics EPS misses by $0.02

Nov 09

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:MRKR - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2027	38	-40	N/A	N/A	1
12/31/2026	2	-67	N/A	N/A	1
12/31/2025	4	-44	N/A	N/A	1
12/31/2024	5	-11	N/A	N/A	1
9/30/2024	5	-10	-9	-9	N/A
6/30/2024	4	-10	-11	-11	N/A
3/31/2024	3	-12	-14	-14	N/A
12/31/2023	3	-14	-16	-16	N/A
9/30/2023	3	-14	-20	-20	N/A
6/30/2023	4	-17	-27	-27	N/A
3/31/2023	4	-14	-18	-21	N/A
12/31/2022	4	-20	-27	-27	N/A
9/30/2022	4	-26	-26	-26	N/A
6/30/2022	3	-33	-27	-25	N/A
3/31/2022	2	-43	-36	-31	N/A
12/31/2021	1	-42	-30	-27	N/A
9/30/2021	N/A	-41	-35	-28	N/A
6/30/2021	N/A	-36	-34	-27	N/A
3/31/2021	0	-31	-35	-24	N/A
12/31/2020	0	-29	-29	-20	N/A
9/30/2020	1	-25	-24	-19	N/A
6/30/2020	1	-23	-23	-19	N/A
3/31/2020	0	-23	-19	-19	N/A
12/31/2019	0	-21	-19	-18	N/A
9/30/2019	N/A	-152	-20	-20	N/A
6/30/2019	N/A	-151	-18	-18	N/A
3/31/2019	0	-150	-16	-16	N/A
12/31/2018	0	-148	-15	-14	N/A
9/30/2018	0	-15	-11	-11	N/A
6/30/2018	0	-15	N/A	-9	N/A
3/31/2018	0	-12	N/A	-9	N/A
12/31/2017	0	-11	N/A	-8	N/A
9/30/2017	0	-10	N/A	-8	N/A
6/30/2017	N/A	-8	N/A	-8	N/A
3/31/2017	N/A	0	N/A	-8	N/A
12/31/2016	N/A	-2	N/A	-7	N/A
9/30/2016	N/A	-3	N/A	-6	N/A
6/30/2016	N/A	28	N/A	-5	N/A
3/31/2016	N/A	-38	N/A	-4	N/A
12/31/2015	N/A	-34	N/A	-4	N/A
9/30/2015	N/A	-33	N/A	-4	N/A
6/30/2015	N/A	-63	N/A	-3	N/A
3/31/2015	N/A	-2	N/A	-3	N/A
12/31/2014	N/A	-31	N/A	-2	N/A
9/30/2014	N/A	-34	N/A	-1	N/A
6/30/2014	N/A	-33	N/A	-1	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que MRKR siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que MRKR siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que MRKR siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (70.7% al año) de MRKR crezcan más rápidamente que los del mercado US (9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (70.7% al año) de MRKR crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de MRKR se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2025/01/05 05:34
Precio de las acciones al final del día	2025/01/03 00:00
Beneficios	2024/09/30
Ingresos anuales	2023/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .

Fuentes analistas

Marker Therapeutics, Inc. está cubierta por 8 analistas. 1 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Kristen Kluska	Cantor Fitzgerald & Co.
Yun Zhong	Janney Montgomery Scott LLC
Aydin Huseynov	Ladenburg Thalmann & Company

Marker Therapeutics Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates increase by 277%

Price target decreased to US$2.17

Consensus revenue estimates fall by 41%

Price target decreased to US$3.63

Price target decreased to US$5.63

Recent updates

Insufficient new directors

Marker Therapeutics, Inc. announced that it has received $16.1 million in funding

Marker Therapeutics, Inc. announced that it expects to receive $16.1 million in funding

Marker Therapeutics, Inc. Provides Clinical Update on MT-601 in Patients with Lymphoma

Marker Therapeutics Receives $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas to Support the Investigation of Mt-601 in Patients with Pancreatic Cancer

Marker Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $11.431731 million.

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Second quarter 2024 earnings released: US$0.25 loss per share (vs US$0.47 loss in 2Q 2023)

New minor risk - Share price stability

First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.48 loss in 1Q 2023)

New major risk - Revenue and earnings growth

Marker Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Full year 2023 earnings released: US$1.59 loss per share (vs US$3.58 loss in FY 2022)

Marker Therapeutics, Inc. Receives Approval from United States Adopted Name, Council and International Nonproprietary Names Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

New major risk - Share price stability

Marker Therapeutics, Inc. Reports Clinical Update on the Apollo Study

Marker Therapeutics, Inc. Announces Complete Response in First Lymphoma Patient Treated with MT-601 After Car T Relapse

Second quarter 2023 earnings released: US$0.47 loss per share (vs US$1.11 loss in 2Q 2022)

Marker Therapeutics, Inc. Announces Zedenoleucel, Its Multi-Tumor-Associated Antigen (Multitaa)-Specific T Cell Product Candidate, Mt-401

Marker Therapeutics, Inc. Appoints Eliot M. Lurier as Interim Chief Financial Officer

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells After Hypomethylating Agent Administration

Marker Therapeutics, Inc. Reports Pre-Clinical Data of Its MT-601 multiTAA-Specific T Cell Product Candidate in Lymphoma Cells

Marker Therapeutics, Inc. Appoints Monic Stuart, M.D., as Chief Medical Officer

Marker Therapeutics, Inc. announced that it expects to receive $25 million in funding from Lincoln Park Capital, LLC

Marker Therapeutics Announces U.S. Food and Drug Administration Clearance of IND for MT-601, Its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer

Consensus revenue estimates increase by 277%

Price target decreased to US$2.17

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Marker Therapeutics, Inc. Announces Resignation of Anthony Kim as Chief Financial Officer, Effective September 30, 2022

Marker Therapeutics Wins $2 Million Grant from U.S. FDA to Support Marker’s Phase 2 Artemis Trial of Mt-401 in Post-Transplant AML

Marker Therapeutics awarded $2M FDA grant for leukemia candidate

Nasdaq Grants an Additional 180-Calendar Day Compliance Period to Marker Therapeutics to Regain Compliance with the Minimum Bid Price Requirement

Consensus revenue estimates fall by 41%

Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71M

Marker Therapeutics, Inc. Announces FDA Clearance of IND for Mt-601, the Six-Antigen Targeted T Cell Therapy for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky

Price target decreased to US$3.63

Marker Therapeutics, Inc., Annual General Meeting, May 24, 2022

Marker Therapeutics, Inc. Announces Frederick Wasserman Will Not Stand for Reelection as Director

Full year 2021 earnings: EPS misses analyst expectations

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Marker Therapeutics, Inc. Announces Clinical Program Updates and Pipeline Expansion

Price target decreased to US$5.63

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics: Passing Through A Catalyst Desert

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics, Inc.(NasdaqGM:MRKR) dropped from Russell 3000E Value Index

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics to Present Multi-Tumor-Associated Antigen (mTAA)-Specific T Cell Manufacturing Robotics Data at the 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Earnings beat expectations, revenue disappoints

Marker Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Trial of Mt-401 in Acute Myeloid Leukemia Following Stem Cell Transplant

Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?

New 90-day high: US$3.19

Marker shares rise as it completes construction of its cGMP manufacturing facility

New 90-day high: US$1.79

Marker Therapeutics, Inc. Announces U.S. Food and Drug Administration Lifted Partial Clinical Hold on Phase 2 AML Clinical Trial

FDA lifts partial hold on Marker Therapeutics's leukemia trial with cell therapy

Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?

New 90-day high: US$1.75

Earnings beat expectations

Marker Therapeutics EPS misses by $0.02

New 90-day low: US$1.43

New 90-day low: US$1.50

Marker Therapeutics, Inc.(NasdaqGM:MRKR) dropped from S&P Global BMI Index

New 90-day low - US$1.65

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura